DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Olson DJ. et al
Significant antitumor activity for low-dose ipilimumab with pembrolizumab immediately following progression on PD1 Ab in melanoma in a phase II trial..
ASCO 2020 Abstract 10004
Access:
We do not assume any responsibility for the contents of the web pages of other providers.